News|Articles|November 20, 2026

TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma

Fact checked by: Ashling Wahner
Listen
0:00 / 0:00

Key Takeaways

  • Sac-TMT became the first TROP2-directed ADC to demonstrate an overall survival advantage in a global phase 3 gastroesophageal adenocarcinoma study versus physician’s choice.
  • TroFuse-015 did not meet the blinded independent central review PFS endpoint, underscoring an OS–PFS discordance despite nominal ORR improvement without formal statistical testing.
SHOW MORE

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Sacituzumab tirumotecan (sac-TMT; MK-2870/SKB264) generated a statistically significant and clinically meaningful improvement in overall survival (OS) vs treatment of physician’s choice in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least 2 prior lines of systemic therapy, meeting the primary end point of the phase 3 TroFuse-015 trial (NCT06356311).¹

However, sac-TMT did not meet the trial’s secondary end point of progression-free survival (PFS) assessed by blinded independent central review. The data are planned to be presented at a future medical conference and submitted to regulatory authorities.

At the final analysis, the OS benefit with sac-TMT was generally consistent across subgroups regardless of TROP2 expression status. Objective response rate (ORR), a secondary end point, showed a nominal improvement favoring sac-TMT over treatment of physician’s choice, although this end point was not formally tested under the prespecified analysis plan.

The safety profile of sac-TMT in TroFuse-015 was consistent with that observed in previously reported studies of the agent, and no new safety signals were identified.

TroFuse-015 Trial: Key Takeaways

  • In TroFuse-015, sac-TMT produced a statistically significant and clinically meaningful OS improvement vs treatment of physician’s choice in patients with advanced gastroesophageal adenocarcinoma who had received at least 2 prior lines of therapy.
  • Sac-TMT did not meet the trial’s secondary end point of PFS by blinded independent central review; ORR was nominally improved but not formally tested.
  • The OS benefit was generally consistent across patient subgroups regardless of TROP2 expression, and no new safety signals were observed.
  • The data are planned to be presented at an upcoming medical meeting and shared with regulatory authorities.

“Sac-TMT is the first TROP2[-directed] antibody-drug conjugate [ADC] to improve OS in a global phase 3 study in advanced gastroesophageal adenocarcinoma compared with treatment of physician’s choice, demonstrating its potential in a particularly challenging disease setting,” Marjorie Green, MD, senior vice president and head of oncology and global clinical development at Merck Research Laboratories, stated in a news release. “There is a tremendous unmet need for therapies that can improve survival for these patients. We look forward to discussing these data with regulatory authorities and sharing [them] with the scientific community on behalf of patients who may benefit.”

What was the rationale for evaluating sac-TMT in gastroesophageal adenocarcinoma?

Treatment options in the third-line setting and beyond are limited for patients with gastroesophageal adenocarcinoma.²

Sac-TMT is an investigational TROP2-directed ADC with a belotecan-derived topoisomerase I inhibitor payload and a bifunctional linker designed to maximize payload delivery to tumor cells and minimize payload loss in circulation throughout the body.¹

Previously, in the gastric/gastroesophageal junction (GEJ) cohort of the phase 1/2 KL264-01 trial (NCT04152499) presented at the 2024 AACR Annual Meeting, sac-TMT at 5 mg/kg every 2 weeks elicited responses, including in patients treated in the third-line setting or later.³

What was the design of TroFuse-015?

The randomized, open-label, multicenter, global trial enrolled 473 patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least 2 prior lines of systemic therapy.¹ Eligible patients were at least 18 years; had measurable disease per RECIST 1.1 criteria by investigator assessment; had experienced disease progression after at least 2 prior lines of therapy, including a fluoropyrimidine and a platinum doublet; and had an ECOG performance status of 0 or 1.² Patients were eligible regardless of HER2 status, although those with HER2-positive disease needed to have previously received trastuzumab (Herceptin).⁴ Patients also needed to provide a tumor tissue sample for central TROP2 testing before random assignment. Key exclusion criteria included prior treatment with a TROP2-targeted ADC or a topoisomerase I inhibitor–based ADC or chemotherapy, known active central nervous system metastases or carcinomatous meningitis, grade 2 or higher peripheral neuropathy, or a history of noninfectious pneumonitis or interstitial lung disease that required steroids.²˒⁴

Patients were randomly assigned 1:1 to receive either of the following regimens, with stratification by TROP2 expression, geographic region, and ECOG performance status:¹˒²˒⁴

  • Sac-TMT at 4 mg/kg on days 1, 15, and 29 of each 6-week cycle¹
  • Treatment of physician’s choice consisting of trifluridine/tipiracil (Lonsurf) at 35 mg/m² orally twice daily on days 1 to 5 and 8 to 12 of each 4-week cycle; irinotecan at 150 mg/m² on days 1 and 15 of each 4-week cycle; paclitaxel at 80 mg/m² on days 1, 8, and 15 of each 4-week cycle; or docetaxel at 75 mg/m² on day 1 of each 3-week cycle

OS served as the primary end point. Secondary end points included PFS, ORR, and duration of response, each assessed per RECIST 1.1 criteria by blinded independent central review, as well as safety and tolerability.

What are the next steps for developing sac-TMT and other ADCs in gastroesophageal cancer?

TroFuse-015 is the second positive phase 3 readout from the TroFuse program, which comprises 18 ongoing global phase 3 trials evaluating sac-TMT across tumor types including endometrial, bladder, breast, cervical, gastric, non–small cell lung, and ovarian cancers, as monotherapy and in combination with immunotherapy.¹ In patients with endometrial cancer, sac-TMT improved PFS and OS vs treatment of physician’s choice in the phase 3 TroFuse-005 trial (NCT06132958) and is under FDA priority review in that setting.⁵

Other ADCs are also advancing in development in patients with previously treated gastroesophageal cancer. On November 19, 2026, the FDA granted priority review to a biologics license application for sonesitatug vedotin (Sone-Ve; CMG901; AZD0901), a claudin 18.2–directed ADC, for the second-line or later treatment of patients with locally advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma with claudin 18.2 expression on at least 25% of tumor cells.⁶ The application is supported by data from the phase 3 CLARITY-Gastric01 trial (NCT06346392), and a target action date is anticipated in the second quarter of 2027.

References

  1. Merck announces TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT) met primary endpoint of overall survival (OS) in third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. News release. Merck. November 20, 2026. Accessed November 20, 2026. https://www.merck.com/news/merck-announces-trofuse-015-trial-evaluating-sacituzumab-tirumotecan-sac-tmt-met-primary-endpoint-of-overall-survival-os-in-third-line-or-later-locally-advanced-unresectable-or-metastatic-gastroes/
  2. Wainberg ZA, Van Cutsem E, Shitara K, et al. MK-2870-015: a phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA). Ann Oncol. 2024;35(suppl 2):S909-S910. doi:10.1016/j.annonc.2024.08.1537
  3. Rodon J, Wainberg ZA, Zhang M, et al. Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a phase 2 study. Cancer Res. 2024;84(suppl 7):CT038. doi:10.1158/1538-7445.AM2024-CT038
  4. A study to evaluate sacituzumab tirumotecan (MK-2870) in advanced/metastatic gastroesophageal adenocarcinoma (MK-2870-015) (TroFuse-015). ClinicalTrials.gov. Updated October 22, 2026. Accessed November 20, 2026. https://clinicaltrials.gov/study/NCT06356311
  5. Sacituzumab tirumotecan (sac-TMT) reduced the risk of death by 32% and the risk of disease progression or death by 41% compared to chemotherapy in certain patients with advanced or recurrent endometrial cancer. News release. Merck. October 26, 2026. Accessed November 20, 2026. https://www.merck.com/news/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial/
  6. Sonesitatug vedotin granted priority review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers. News release. AstraZeneca. November 19, 2026. Accessed November 20, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/sonesitatug-vedotin-granted-priority-review-us-for-2nd-later-line-treatment-patients-with-cldn182-positive-advanced-gastric-gej-cancers.html

Related to this article